United States Cancer CDK Inhibitors Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Cancer CDK Inhibitors Market reached US$ 9.3 billion in 2023 and is expected to reach US$ 13.8 billion by 2031, growing at a CAGR of 5.2% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In June 2025, Gilead Sciences and Kymera Therapeutics entered into an exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders. This collaboration aims to accelerate the development and commercialization of targeted therapies for various cancers, including breast cancer and other solid tumors.

✅ In May 2025, Pfizer initiated clinical trials for tegtociclib (PF-07104091), a CDK2 inhibitor, in patients with advanced solid tumors. The Phase 1b/2 studies are evaluating both monotherapy and combination approaches, focusing on hormone receptor-positive breast cancer.

✅ In March 2025, preclinical research published in Cancer Cell reported that atirmociclib, a next-generation CDK4-selective inhibitor, exhibited enhanced anti-tumor activity and reduced predicted toxicity compared to FDA-approved dual CDK4/6 inhibitors. Clinical trials are ongoing to validate these findings.

Japan: Recent Industry Developments

✅ In April 2025, Roche's Japanese subsidiary received approval for inavolisib (Itovebi), a selective PI3Kα inhibitor, for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer. This approval marks a significant advancement in targeted cancer therapies in Japan.

✅ In March 2025, Daiichi Sankyo announced the initiation of clinical trials for a novel CDK4/6 inhibitor in combination with chemotherapy for patients with advanced breast cancer. The company aims to enhance treatment efficacy and patient outcomes through this innovative approach.

✅ In February 2025, the Japanese government allocated additional funding to support the development of next-generation cancer therapies, including CDK inhibitors. This investment underscores Japan's commitment to advancing cancer treatment and research.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cancer-cdk-inhibitors-market?sb

Recent Mergers and acquisitions:

United States: Recent M&A Activity

✅ In August 2025, Bayer announced a deal worth up to $1.3 billion with U.S.-based Kumquat Biosciences to develop a potential new cancer drug targeting the KRAS G12D mutation. This mutation is involved in about 25% of human cancers, including pancreatic, colorectal, and lung cancers. Kumquat will lead the initial Phase Ia clinical trials, while Bayer will handle later-stage development and commercialization.

✅ In August 2025, Incyclix Bio secured an $11.25 million extension to its Series B financing. The funding will advance the Phase 1/2 clinical trial of INX-315, a novel, potent, and selective CDK2 inhibitor, for the treatment of patients with recurrent advanced/metastatic cancer, including CDK4/6 inhibitor-resistant ER+/HER2- breast cancer or CCNE1-amplified solid tumors.

Japan: Recent M&A Activity

✅ In August 2025, Taiho Pharmaceutical of Japan announced the acquisition of Switzerland's Araris Biotech for up to $1.14 billion. Araris focuses on next-generation antibody-drug conjugates to target tumors, enhancing Taiho's oncology portfolio.

Key Players:

=> Pfizer Inc., Eli Lilly and Company, Novartis AG., Sanofi-Aventis, Merck & Co, Amgen, Bayer Pharmaceuticals, Piramal Life, G1 Therapeutics, AstraZeneca among others.

Growth Forecast Projected:

The Global Cancer CDK Inhibitors Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cancer CDK Inhibitors Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-cdk-inhibitors-market

Key Segments:

➥ By Drug Type: Palbociclib, Ribociclib, Abemaciclib
➥ By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer
➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Cancer CDK Inhibitors Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cancer CDK Inhibitors producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cancer CDK Inhibitors revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-cdk-inhibitors-market?sb

FAQ

What is the current size of the Cancer CDK Inhibitors Market?

A: In 2023, the Cancer CDK Inhibitors Market was valued at US$ 9.3 billion, reflecting its strong industry presence.

Q2: How large is the Cancer CDK Inhibitors Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Cancer CDK Inhibitors Market will grow to around US$ 13.8 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Cancer CDK Inhibitors Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.